News - Myeloma Patients Europe

Latest News

The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patients

July 25, 2025

Two belantamab mafodotin (Blenrep®) combinations, with bortezomib and dexamethasone or pomalidomide and dexamethasone, are now authorised for use in the European Union. The decision follows an earlier positive recommendation of European Medicines Agency (EMA) Committee…

Europe’s Beating Cancer Plan and its progress to date on rare cancers

February 28, 2025

Among the biggest policy initiatives targeting cancer at the European Union (EU) level, Europe’s Beating Cancer Plan is one of the most important and ambitious. Launched in 2021, it set to “tackle the entire disease…

MPE webinar on ASH 2024 myeloma and AL amyloidosis highlights

November 29, 2024

Myeloma Patients Europe (MPE) will host a webinar covering key updates on myeloma and AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting, which will take place from 7–10 December 2024 in…

MPE provided feedback on the HTA Implementing Regulation on joint scientific consultations on medical devices and in vitro diagnostic medical devices at Union level

November 27, 2024

This week MPE provided feedback on the draft of the fifth implementing act (out of six planned to be adopted this year) paving the road for the application of the Health Technology Assessment (HTA) Regulation…

EMA CHMP gives positive opinion on isatuximab combination for newly diagnosed myeloma patients

November 20, 2024

On 14 November 2024, the Committee for Medicinal Products for Human Use (CHMP) recommended adding a new indication for isatuximab, a monoclonal antibody treatment marketed by Sanofi as Sarclisa ®. The CHMP is the European…

MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level

October 29, 2024

Yesterday 28 October, MPE provided feedback, as part of a public consultation open to all categories of stakeholders, on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union level.…

A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and Wales

July 17, 2024

After the approval of the first bispecific antibody for myeloma last month, the National Institute for Health and Care Excellence (NICE, the United Kingdom’s public body for medicine appraisals) approved today, 16 July 2024, a…

The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and Wales

July 9, 2024

On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an ongoing clinical trial showed that…

July

August 2025

September

MO
TU
WE
TH
FR
SA
SU

28
29
30
31
1
2
3

4
5
6
7
8
9
10

11
12
13
14
15
16
17

18
19
20
21
22
23
24

25
26
27
28
29
30
31

Events for August

31st

No Events

Latest News

August 2025

Events for August

1st

Events for August

2nd

Events for August

3rd

Events for August

4th

Events for August

5th

Events for August

6th

Events for August

7th

Events for August

8th

Events for August

9th

Events for August

10th

Events for August

11th

Events for August

12th

Events for August

13th

Events for August

14th

Events for August

15th

Events for August

16th

Events for August

17th

Events for August

18th

Events for August

19th

Events for August

20th

Events for August

21st

Events for August

22nd

Events for August

23rd

Events for August

24th

Events for August

25th

Events for August

26th

Events for August

27th

Events for August

28th

Events for August

29th

Events for August

30th

Events for August

31st

Myeloma Patients Europe AISBL

PopUp